Company intelligence / Profile preview

vVARDIS

Ownership: Private
Development stage: Other

Overview

vVARDIS has developed a proprietary biomimetic platform, Curodont™, which enables drill-free, regenerative treatment of early-stage tooth decay. Their approach is supported by over 25 years of research and more than 200 scientific publications, including meta-analysis and peer-reviewed clinical studies. Hundreds of thousands of patients have been treated successfully with their products.

Therapeutic areas: Other
Modalities: DeviceBiologic (biomimetic dental materials)
Industry: Biotech

Partnerships

OrbiMed

Beyond the preview

Go deeper on vVARDIS.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on vVARDIS.

Explore the full profile